1

#BlackLivesMatter

MF-11 Eleventh Microfluidics Consortium

MF11.3 Video Meeting

Boston, USA June 10

Agenda V11

Member Profiles

Zoom Sign in Arrangements

During the Covid19 Pandemic we are re-inventing MF11 as a virtual

service – delivering consortium meetings over Zoom

These video meetings are designed to replace most of the content /

processes of MF11.3. Some sessions are Members only, others are

2

open to registered non-members. We are experimenting with ‘Member

Booths’ and ‘Pods’ for private conversations/demos.

The Eleventh Microfluidics Consortium brings together current and future stakeholders from across a wide range of backgrounds with a shared interest in facilitating the growth of the microfluidics industry through better understanding of the challenges, opportunities and choices which it faces.

Our current membership includes: BD Biosciences (USA), IPGG (F) ;EV Group (A) Philips (NL); Micronit (NL); Danaher (USA); Dolomite (UK) ; Fluigent (F); MicroCAPS (CH), National Research Council of Canada (CAN); Lonza (CH) ; IMT (CH), Posalux (CH); Sartorius (USA), Susos (CH), Web Industries (USA); Cryopak (USA), z-microsystems (A); Zeon Speciality Materials (USA) and University of Cambridge (UK).

We organize closed meetings for our members on both sides of the Atlantic where we seek to promote our mission “to grow the market for microfluidics enabled products and services” by

- Finding shared interest across the landscape of applications - Championing modularity and standards where appropriate - Engaging with key industry influencers

While helping our members to do deals along the way.

On this occasion we are delighted to be hosted by the Blainey Lab at the Broad Institute and supported by Fluigent. We are also working with our good friends at FluidicMEMs

Broad Institute of MIT and Harvard was launched in 2004 to improve human health by using genomics to advance our understanding of the biology and treatment of human disease, and to help lay the groundwork for a new generation of therapies.

The institute was founded to seize the opportunity that arose from the Human Genome Project -- the international effort that successfully deciphered the entire human genetic code. Despite that accomplishment, scientists knew they still lacked a clear understanding of the genetic basis of disease, and how to translate that understanding into more effective prevention, diagnosis, and treatment.

To reach these goals, it was clear that a new type of research institution had to be created. The traditional academic model of individual laboratories working within their specific disciplines was not designed to meet the emerging challenges of biomedicine. To gain a comprehensive view of the human genome and biological systems, they instead had to work in a highly integrated fashion.

3

That meant working in nimble teams that combined biology, chemistry, mathematics, computation, and engineering with medical science and clinical research. It also meant working at a scale usually seen in industry, with access to world-class infrastructure. At the same time, this institution had to foster an atmosphere of creativity, risk-taking, and open sharing of data and research. Finally, this new model needed to seek collaborations beyond its borders.

Broad Institute is an “experiment” in this new way of doing science. It spans some of Boston’s leading institutions (Harvard, MIT, and Harvard-affiliated hospitals) and scientific disciplines (biology, chemistry, medicine, computer science, and engineering). Today, the Broad community includes more than three thousand scientists, committed to advancing research in areas including infectious disease, cancer, psychiatric research, and cardiovascular disease.

Embedded in this new approach to doing science, are our values including:

Propelling the understanding and treatment of disease Broad Institute is empowering a revolution in biomedicine to accelerate the pace at which the world conquers disease.

Collaborating deeply Broad Institute is a mission-driven community that brings together researchers in medicine, biology, chemistry, computation, engineering, and mathematics from across MIT, Harvard, and the Harvard-affiliated hospitals, along with collaborators around the world.

Reaching globally Broad Institute is committed to addressing medical challenges across the world, including collaborating with scientists and public health experts to address important needs in developing countries

Empowering scientists Broad Institute fosters an environment in which scientists can take risks on bold ideas with transformative potential.

Building partnerships Broad Institute works to build and sustain international consortia to speed discovery in areas including psychiatric research, infectious disease, cardiovascular disease, and cancer.

Sharing data and knowledge Broad Institute is committed to making the extensive data, methods, and technologies it generates rapidly and readily accessible to the scientific community to drive biomedical progress around the world. (Read about our principles for disseminating scientific innovations)

Promoting inclusion Broad Institute believes that progress in biomedical research requires a fully inclusive community across sex, race, ethnicity, sexual orientation, age, and gender identity.

4

Zoom meeting arrangements:

We will have several virtual rooms:

- Main Auditorium open to: o Members – who will have full audio/video/screen-share/file

share/chat/see other participants rights o Non-Members - who will be able to see/hear the proceedings and ask

questions but not screen/file share

- 1Members Executive Lounge Open to MF11 members only and with full A/V meeting facilities for confidential consortium sessions.

- Members’ Private Booths. Hosted by individual members who can invite any delegates to join them at any time for discussions and shared presentation materials. In Bostonwe are expecting booths hosted by:

-

- - 1-2-1 Discussion Pods Members can invite anyone to join them for private

video discussions. (Its like stepping out of the room at a conference!) -

- See logistics section below for details of how to join this Zoom meeting and visit the private booths.

5

Meeting Agenda June 10

All times are US East Coast Time (= UK time -5, European time -6,

Pacific time +3)

8:30 Zoom login, Audio-Visual Checks and Chat - It’s the new coffee and biscuits!

8:45 Location: Main Auditorium

Introduction and Welcome : House Rules and How to get the best out of the meeting

Peter Hewkin and Alice Hewkin virtual meeting hosts - CfBI

09:00 Location: Main Auditorium

All Microphones to mute, please

Session 1 “Research”

We will hear from leading microfluidics researchers in the Cambridge/Boston

Cluster. Each talk will be followed by Q&A moderated by Peter Hewkin. Please ‘raise

your hand’ or chat to Alice/Peter if you want to speak – and be ready to unmute

your microphone

Paul Blainey: Core member of the Broad Institute of MIT and Harvard

Prof. Blainey completed his undergraduate degrees in Mathematics and Chemistry at the University of Washington and a MA in Chemistry from Harvard University. Paul Blainey continued his doctoral studies in Physical Chemistry at Harvard University under the joint supervision of Profs. Xiaoliang Sunney Xie and Gregory L. Verdine. He held a postdoctoral appointment at Stanford University where he developed high-throughput microoptofluidic methods for whole-genome amplification of DNA from individual, uncultivated microbial cells in Prof. Stephen Quake’s laboratory. Paul joined MIT as an

Assistant Professor of Biological Engineering in 2012.

Broadly, research in the Blainey group integrates new microfluidic, optical, and molecular tools for application in biology and medicine. We emphasize quantitative single-cell and single-molecule approaches, aiming to enable multiparametric studies with the power to reveal the workings of natural and engineered biological systems across a range of scales.

6

“Identifying and Rationally Modulating Cellular Drivers Of Enhanced Immunity” Alex K. Shalek: Pfizer-Laubach Career Development Associate Professor at MIT

The interdisciplinary research in the Shalek lab is directed towards the creation and implementation of new approaches to elucidate cellular and molecular features that inform tissue-level (dys)function across the spectrum of human health and disease. This encompasses both the development of broadly enabling technologies as well as their application to characterize, model, and rationally control complex multicellular systems. With respect to technology development, the lab couples genomics, chemical biology, and nanotechnology to establish

accessible, broadly applicable cross-disciplinary platforms that enable them and others to profile and control cells and their interactions within complex multicellular systems. In addition to sharing this toolbox to empower mechanistic scientific inquiry across the global research community, the lab is applying it to uncover principles that inform ensemble immune responses within tissues, focusing on the roles of cellular heterogeneity and cell-to-cell communication. Current studies seek to methodically dissect human disease to understand links between cellular features and clinical observations, including how: immune cells coordinate balanced responses to environmental changes with tissue-resident cells; host cell-pathogen interactions evolve across time and tissues during HIV-1 and M. Tuberculosis infection; and, tumor cells evade homeostatic immune activity. From these collective observations, the lab aims to construct generalizable models of how disease alters tissue homeostasis and function on the cellular level that can be tested to aid in the design of therapeutic and prophylactic interventions to improve human health. The lab’s work transforms thinking about human disease as natural perturbations to the human immune system.

Luke Lee - Professor, Harvard Medical School, Harvard University, and Brigham and Women's Hospital

Professor Lee received both his BA and PhD from UC Berkeley. He joined the faculty at UC Berkeley in 1999 after more than a decade of industry experience. He became the Lester John and Lynne Dewar Lloyd Distinguished Professor of Bioengineering in 2005. He also served as the Chair Professor in Systems Nanobiology at the Swiss Federal Institute of Technology (ETH, Zürich) from 2006 to 2007. He became Arnold and Barbara Silverman Distinguished Professor in 2010 and was reappointed again in 2015. His work at the interface of biological, physical, and engineering sciences for

medicine has been recognized by many honours that include the IEEE William J. Morlock Award, NSF Career Award, Fulbright Scholar Award, and the HoAm Prize. He is a Fellow of the Royal Society of Chemistry and the American Institute of Medical and Biological Engineering (AIMBE). His current research interests include quantum electron transfers in living organisms, molecular diagnostics of infectious and neurodegenerative diseases, and in vitro neurogenesis, with a focus both on studying fundamental quantum nanobiology and on solving ill-defined problems of global healthcare.

7

10:45 close

Members and non-members free to chat by text in the main auditorium and visit the

member booths. If you want to be allocated to a particular member booth chat with

Alice.

11:00 Session 2: “What’s Up?” - Members presentations.

Location Main Auditorium

This session is an opportunity for members to present on their recent work and

achievements. Each talk will be followed by Q&A.

Sartorius Stedim Biotech – Samin Akbari The Sartorius Group is a leading manufacturer and

provider of innovative laboratory instrument and

consumables for biotech industry. The lab products and

services division concentrates on serving the needs of

laboratories performing research and quality control at

biopharma companies and academic research

institutes.The Bioprocess Solutions Division has a broad

product portfolio focusing on single-use solutions to help

customers manufacture biotech medications and vaccines safely and efficiently. Currently,

more than 8,100 people work at the Group’s approximately 60 manufacturing and sales

sites, serving customers around the globe.

LaunchWorks – Jeff Kelly “Scaling Up Operations during a Pandemic: Addressing the challenges presented to a Service organization”

Scaling an organization is never a simple task as predicting

the future can never be 100% accurate. Plans are made,

pressure tested, adjusted and finalized to the best of our

knowledge. It is a new year, 6 months of planning and

forecasting the needs for the next 18 months are now

complete. The year’s trajectory is set as January

starts. Six week’s later, the world has turned upside

down. 95% of the expected business is put on hold due to

shelter-in-place effects; replaced 4X by COVID-19

diagnostic and serology tests. This is one company’s story

on we navigated the challenges, learned lessons,

reassured our clients, engaged new clients, protected our team, supported our community and

prepared for the new normal during the first four months of the pandemic.

8

Zeon Speciality Materials – Larry Atupen ZEON SPECIALTY MATERIALS (ZSM) is a wholly owned

subsidiary of ZEON CORPORATION, a global world leader

in the production of specialty elastomers, polymers, and

chemicals. ZEON manufactures ZEONEX and ZEONOR

Cyclo Olefin Polymer; an ultra-pure, inert, low-fluorescence

polymer with glass-like transparency making them ideal

choices for optical, diagnostic and life science devices.

With a headquarters in San Jose, CA ZSM has positioned

itself to not only provide distribution and technical support

for COP but also provide microfluidic prototyping

services to further aid companies in their development process.

Susos – “Bio-functional coatings enabling high sensitivity and high specificity in surface-bound diagnostics - going beyond the state of the art” Christian Mathis

Christian Mathis-Ullrich is Head of Business Development

at SuSoS AG a company specialised in surface

functionalization using thin-film polymer coatings. In the

wake of the recent SARS CoV-19 pandemic our

bifunctional coatings are supporting efforts of partners to

enable rapid virus and antibody testing using different

technology platforms.

In surface based assays the adsorption of non-specific

moieties and lack of adsorption of to be detected moieties

on the sensing domain of a test can lead to a false reading,

limiting their sensitivity for virus detection. While increased sensitivity can be obtained by

improved sensing methods this higher sensitivity leads to a reduction in specificity, if non-

specific attachments are not prevented. The challenge is to reduce non-specific interactions,

while providing a highly specific attachment site for target biomolecules.

Using SuSoS proprietary surface technologies, PAcrAm™ and AziGrip4™, it is possible to

create surfaces prohibiting non-specific binding, while allowing for specific capturing of to-be-

detected biomolecules. The technology has been successfully demonstrated and

industrialized in commercially available microfluidics point-of-care in-vitro diagnostic products

produced in high volumes."

9

12:00 Session 3: Keynote Mobile Phone controlled Point-of-Care Diagnostics

Location: Main Auditorium

Yuksel Temiz : Research Staff Member in the Science & Technology department at

IBM Research – Zurich. Mobile Phone controlled Point-of-Care Diagnostics

. Yuksel received his B.Sc. and M.Sc. in electrical

engineering, specializing on analog circuit design for

micro-electromechanical systems. He obtained his

Ph.D. degree in 2012 from École Polytechnique

Fédérale de Lausanne (EPFL), where he developed

3D chip integration and post-CMOS processing

techniques for biosensing applications. Since 2012,

he has been working in the Precision Diagnostics

group of IBM Research – Zurich. He has co-invented

over 20 patents, and co-authored 50 publications and

2 book chapters primarily relating to capillary-driven

microfluidics, bead-based immunoassays, system integration and packaging,

microfabrication, and IoT devices. His current research focuses on innovative

microfluidic technologies and portable electronic platforms for point-of-care

diagnostics, particularly ultra-miniaturized immunoassays for mobile health application

Members and non-members free to chat by text in the main auditorium and visit the

member booths. If you want to be allocated to a particular member booth chat with

Alice.

12:45 close / break

Members and non-members free to chat by text in the main auditorium and visit the

member booths at any point during the day. If you want to be allocated to a particular

member booth chat with Alice.

10

The formal programme for Non-Members finished here. However, Members and

non-members free to chat by text in the main auditorium and visit the member

booths at any time from here on. If you want to be allocated to a particular member

booth chat with Alice.

13:00 Location: Members Executive Lounge. MF 11 Members will automatically be

allocated to the Executive Lounge. They can go there by using the ‘breakout room’ button on their

tool bar. They can return to the main auditorium when they wish by pressing the ‘leave breakout

room button’ or ‘leave room’ button (depending on PC or mobile operating system).

Please do not press leave meeting – you will have to rejoin!!

Session 4: “Microfluidics Hotseat”. Pitches

from early stage microfluidics enabled companies

seeking to engage with the MF11 Consortium

David Deetz – Founder Ativa Medical

Ativa is a privately held, emerging growth diagnostic

company. We are working relentlessly to deliver an

affordable diagnostic solution that consolidates

blood, metabolic and urine testing to decentralized

healthcare settings globally.

With vast in vitro diagnostics experience, our

leadership team and board of directors has a proven

history of successfully developing and

commercializing novel point-of-care (POC) diagnostic

technologies.

We are driven to change lives.

Our goal is to develop a system with new diagnostic processes that:

Facilitate faster diagnoses, reducing the time from symptom onset to diagnosis Reduce the time, distance and cost barriers for people to get diagnosed Identify unknown conditions sooner and facilitate more accurate diagnoses

11

Murat Cirit – co Founder Javelin Biotech

Javelin Biotech launched in the summer of 2019 with a team of scientists focused on developing solutions for specific challenges of drug discovery and development. Drawing on our experiences with NIH and DARPA in the human-body-on-a-chip programs and working with pre-clinical scientific teams from Big Pharma, we believe that new microphysiological systems and computational models have matured to a level that they can be purpose built; designed and integrated for specific applications like delivering human PK parameters during lead optimization. Our mission is to improve late stage drug discovery, efficiently using resources to advance

candidate therapies.

We are a venture-backed company with additional funding from the National Center for Advancing Translational Sciences (NCATS) at NIH. We are located in Woburn, MA

Jeff Campbell – Medic Life “Smart Medical Toilet”

At Medic Life, we believe in the power of preventative medicine to improve quality of life for all people. From early diagnosis to a complete personalized picture of well-being, Medic technologies deliver a health data revolution into the hands of each client, all without interfering in their normal daily routine. The "smart" medical toilet has potential to become a versatile and highly available health and wellness tool, providing deep health insights while requiring little to no extra effort from users. The Medic system gathers patient medical data on vital signs, wellness and overall health. Our

engineering teams work together to develop medical grade sensors, diagnostic peripherals, and health monitors that build a view of what “wellness” looks like for every unique person. Medic is creating the future of health care with the development of complete health monitoring solutions for preventative care.

12

Colin Brenan – 1 Cell Bio

1CellBiO Inc. researches, develops and commercializes innovative high throughput solutions for single cell genomics analysis. Our first product is inDrop, a high throughput method for single cell expression profiling from 100 to many tens of thousands of cells.

Each talk followed by Q & A hosted by Peter Hewkin. 14:00 Close

Members and non-members free to chat by text in the main auditorium and visit the

member booths at any time. If you want to be allocated to a particular member booth

chat with Alice.

14:00 Members Executive Lounge Session 4: Standards

NIST – Darwin Reyes - Hernandez

Dr. Reyes-Hernandez is a biomedical engineer in the Biomedical Microtechnologies Group in the Microsystems and Nanotechnology Division of the Physical Measurement Laboratory (PML) at the National Institute of Standards and Technology (NIST). He received a B.S. and Ph.D. in chemistry from the University of Puerto Rico, and an M.S. in Applied Biomedical Engineering from Johns Hopkins University. In his doctoral work, he combined the fields of environmental analytical chemistry and toxicology. In it, he chemically characterized airborne particulate matter from an area in Puerto Rico of high incidence of cancer, asthma, and other respiratory diseases, using cell-based toxicological assays. After

completing his Ph.D. he was awarded with a National Science Foundation (NSF) Postdoctoral Fellowship to work with Professor Andreas Manz at Imperial College, London, U.K., where he worked for two years. During this postdoctoral experience, he worked with microfluidic devices in developing two-dimensional separation systems and analog computing using glow discharge in microfluidic chips.

Dr. Reyes-Hernandez was awarded in 2002 with a National Research Council/NIST postdoctoral fellowship to work at NIST, USA. He is currently working in the development of microfluidic systems with electronic manipulation and measurement

13

for cell-based assays and drug screening; electronic flow measurement sensors/methods; cell-substrate biomimetic interfaces with tunable elasticity; additive manufacturing (3D Printing) using fused deposition modeling (FDM) for microfluidic devices; and thin, flexible wearable sensors.

During his time at NIST, Dr. Reyes-Hernandez has been part of various intramural funded projects including research funded by the Advanced Technology Program (ATP), Director's Reserve Funds, Innovations in Measurement Science Program (IMS) and more recently, the NIST on a Chip Initiative.

Ali Lashkapour from Douglas Densmore–Living Computing Project

Computing in the 21st century is extremely exciting, diverse, and democratized. Using just a few simple concepts and a personal computer, people of all ages and backgrounds can create smartphone applications, social media networks, and amazing electronic gadgets. Each of these creations can then be shared, modified, and extended by others. The Living Computing Project is going to let us “program biology” and democratize the process as society has with electronic computing. Programming biology is going to be the key to solving many of the 21st century’s most

pressing human health, agricultural, and materials challenges.

A key aspect of the Living Computing Project is the design automation of microfluidic

devices. By borrowing the design automation concepts from the field of electronics

and applying it to the field of microfluidics, microfluidic devices can be created through

high-level specification. CIDAR lab has developed open-source tools such as DAFD,

3DµF, and Fluigi to lower the barrier to entry to microfluidics and reduce the

development time and cost typically associated with microfluidics. Once complete, this

project will provide a comprehensive and freely available set of building blocks to

engineer microfluidic systems

Members and non-members free to chat by text in the main auditorium and visit the

member booths at any time. If you want to be allocated to a particular member booth

chat with Alice.

15:00 Close

14

15:30 Members Executive Lounge – ParticleGEN manufacturing companies

strategies and tactics (closed session) led by Pavel Abdulkin,

Pavel is Chief Commercial Officer at MicroCAPS.

Microcaps enables precision microencapsulation at

industrial scale. We develop formulations, supply

equipment and provide consumables necessary to take

complex microencapsulation projects from proof of

principle to industrial implementation. We work with

pharmaceutical, biomedical and cosmetics companies on

projects such as active ingredient protection, controlled

release and targeted delivery.

16:30 close

15

Delegate List

Name Surname Organisation Country

Pavel Abdulkin Microcaps CH

Aytan Abraham Lonza US

Samin Akbari Sartorius US

Don Arnold Veristad US

Mark Aruda Fluigent US

Mariam Assadian Heidenhain US

Larry Atupen Zeon SMI US

Maurice Barakat Cryopak US

Paul Blainey MIT US

John Boogaard Adhesives Research IRL

Abir-Wissam Boudaoud CETIAT F

Bojan Boskovic CfBI UK

Nicholas Brancazio Broad Institute US

Colin Brenan 1 Cell Bio US

Monica Brivio Micronit NL

Julian Burke Danaher / Leica UK

Jeff Campbell Medic Life US

Arnaud Cartier Fluigent F

Tianyi Chang Broad Institute US

Pin Chen BD US

Murat Cirit Javelin Bio US

Jonathan Cottet MIT US

Elodie Couttenier IPGG F

Sammy Datwani Inscripta Inc US

Robin de Bruin Philips NL

David Deetz Ativa Medical US

Bernd Dielacher EV Group A

Jacques Fattaccioli IPGG F

Hirotaro Fujiki Zeon Corp Japan

Douglas Goldstein Adhesives Research US

Cedric Goyer Posalux CH

Richard Gray Blacktrace UK

France Hamber Fluigent F

Yusuke Harada DestinHaus US

Meghan Hemond Edge Embossing US

Alice Hewkin CfBI / Zoom Host UK

Peter Hewkin CfBI UK

Li Lun Ho MIT US

Yasuko Horiguchi Zeon Corp Japan

Helena Hu Broad Institute US

Andy Kamholz Edge Embossing US

Jeffrey Kelly Launchworks US

16

Taehong Kwong MIT US

Ali Lashkaripour Boston University US

Darin Latimer Danaher US

Luke Lee Harvard Medical School US

Jas Lee Wolf Greenfield US

Kyungheon Lee Broad Institute US

Christophe Len IPGG US

Leanna Levine Aline US

Tianle Ma Broad Institute US

Callum Marrs Blacktrace US

Christian Mathis Susos CH

Lou Medina Adhesives Research US

Melissa Mendez GSK US

Darren Morofke Danaher US

Mariam Mosaad Broad Institute US

Thomas Muller Fluidic Analytics CH

Marko Nadalin Posalux CH

Birgit Nelsen-Salz Lonza D

Abir Wissam CETIAT F

Joao Paulo Olivier Broad Institute US

Emily Pan Broad Institute US

Robert Pelletier Fluigent US

David Pollard Sartorius US

Bryan Presley Posalux US

Yatian Qu Bay Area Microfluidics Network US

Andy Racher Lonza UK

Rahul Ramesh DestinHaus US

Darwin Reyes NIST US

Mark Olde Riekerink Micronit NL

Derin Sevenler Broad Institute US

Alex Shalek MIT US

Sonia Smith z-microsystems A

Philipp Spuhler BD US

Sebastian Stoeckeler z-microsystems A

Shannon Stott Mass General Hospital US

Clover Su Mass General Hospital US

Sathish Subramanian Broad Institute US

T Onar Tasci Mass General Hospital US

Yuksel Temiz IBM Research CH

Mattias Tidare Danaher / Cytiva S

Soroosh Torabi University of Kentucky US

Samuele Tosatti Susos CH

Alexios Tzannis IMT CH

Joost van Philips NL

Remi Wache IPGG F

Abdul Wasay National Research Council of Canada CAN

Blaise Will Boston Micro Fabrication US

David Wine Broad Institute US

17

Qihua Xu BD US

Jerry Zhao New York Institute of Technology US

Tim Zhu BD US

Ioannis Zervantonakis Broad Institute US

Bold = MF11 Member Organisation (with access to Executive Lounge) Red = Virtual Booth Holder (ask them if you want to visit their booth)

Logistics:

We are going to use the Zoom platform. Delegates have to have Zoom V5.0 and

register in advance of participating (security measures). Follow the links below for

detailed instructions.

- MF11 members register here for free. They can participate in all sessions.

- Non-MF11 members register/pay here. There is a charge and they can only participate in the open sessions.

In the members only session Chatham House Rule applies. Delegates will know who else is

participating in the conversation. Recording is disabled / forbidden. We have made breakout

rooms available for smaller member Zoom meetings. Members wanting to use these should

chat with ‘Alice’ who can place them in a specific ‘chat pod’ with their chosen partner for a

private 1-2-1 video conversation.

You will get the best experience if you use a PC/Laptop (make sure that your mic / camera

work by using the Zoom sound-check feature) – but participation by phone/smart phone is

also possible. We recommend that you keep your video on. If the room gets over crowded we

will mute microphones except for the speaker.

There is no charge for using the Zoom platform – but you might have to pay your

phone/internet company for time/data use.

If you have not used Zoom before, we recommend that you practise. Check out features

like ‘Test mic/video’, ‘Gallery View’/’Speaker View’ ‘Chat’ and ‘Breakout Rooms’. The

participant experience (particularly in the discussions) is best if you enable video .. but this

uses more bandwidth and might cost you more

18

Main Auditorium:

All delegates land here when they join the meeting. They will usually see this screen

Or the live presentations. They can move to their allocated breakout room whenever they like using

the Breakout Room button.

Do not press Leave Meeting – you will have to login again!

MF11 Members’ Executive Lounge:

This has been realized using the ‘Breakout Room’ feature in zoom. All MF11 members

have been allocated access to this room by default. They can use the toolbar breakout

room icon to visit the Executive Lounge and the red ‘leave breakout room’ message

to return to the main auditorium at any time.

MF11 members will automatically be invited to transfer to the Executive Lounge when

Members only sessions are starting.

On arrival in the MF11 Members’ Executive Lounge Members will see this screen:

19

You can return to the Main Auditorium by pressing the red ‘Leave Breakout Room’

button to the right of the toolbar.

Non-MF11 members cannot access the MF11 Members Executive Lounge, but they

can access the member booths. Chat with Alice for help with navigation.

Members Private Booths:

These have been realized using the ‘Breakout Room’ feature in zoom. The Members

with private booths will have a permanent presence in their room – where they can

hold video discussions with visitors, share screens and show presentations at anytime

they like.

We have provided training to booth holder members so they can chat with Alice to ask

for and receive ‘host privileges’ for a few minutes. In this time they can invite delegates

to join them at their booth. This host privilege can only be used by one member at a

time – so their might be a queue – which Alice will manage.

Non-member guests will have access to the booth of their host member. They can

use the breakout room icon to visit this private member booth and the red ‘leave

breakout room’ message to return to the main auditorium.

20

At present we expect to have Member Private Booths for:

- Micronit - Zeon SMI - Fluigent - Launchworks - MicroCAPS - Susos

Where a representative of these companies will welcome you at any time. Companies with

Member Private Booths are able to invite delegates to join them at any time.

On the day we hope to publish a ‘multi-screen cinema’ programme showing what will be

demonstrated at what time in what booth.

Members and Non-Members wanting to visit a Member Private booth other than their

assigned breakout room need to ask the host or the booth owner to change their

assigned room. Send a message by zoom chat to ‘Alice’ or the Booth Owner to do

this. You will then receive an invitation to join your new selected Booth.

We have created a Guide for Virtual booth holders with screen shots of the steps

they need to follow. Alice can share this file with you.

Questions?:

We know that these processes are sub-optimal and expect some rough edges! Please

contact Peter on ceo@cfbi.com or ++44 7951721110 if you have an urgent problem –

or use the chat feature to contact Alice in the Main Auditorium using chat for less

urgent things.